Eric Kam-Chuan Lau, DO
Hematology/Oncology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 2
- 2 carriers
- Offices
- 6
Offices
6 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Hospitals listed: Mills-Peninsula Medical Center · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
2 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Lau’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
2 of 2 plans
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$2,750,052
Medicare paid this office $2,750,052 for 601 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, pembrolizumab, 1 mg | 18 | $499,947 | None |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 12 | $412,579 | None |
| Injection, vedolizumab, intravenous, 1 mg | 12 | $104,294 | None |
| Long return visit (40+ min) | 149 | $61,036 | $168 |
| Injection, eptinezumab-jjmr, 1 mg | 12 | $60,581 | None |
See all 38 services
| Injection, pembrolizumab, 1 mg | 18 | $499,947 | None |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 12 | $412,579 | None |
| Injection, vedolizumab, intravenous, 1 mg | 12 | $104,294 | None |
| Long return visit (40+ min) | 149 | $61,036 | $168 |
| Injection, eptinezumab-jjmr, 1 mg | 12 | $60,581 | None |
| Administration of chemotherapy into vein, 1 hour or less | 97 | $33,180 | $141 |
| Injection, golimumab, 1 mg, for intravenous use | 11 | $26,506 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 185 | $19,749 | $67 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 109 | $17,040 | $29 |
| Return visit (30+ min) | 66 | $12,453 | $120 |
| New patient visit (60+ min) | 46 | $9,002 | $196 |
| Short return visit (20+ min) | 85 | $8,786 | $85 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 13 | $8,063 | None |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $5,808 | $77 |
| Administration of additional new drug or substance into vein, 1 hour or less | 28 | $4,452 | $68 |
| New patient visit (30+ min) | 38 | $3,627 | $95 |
| New patient visit (45+ min) | 23 | $3,625 | $158 |
| Bcg live intravesical instillation, 1 mg | 16 | $3,452 | None |
| Injection, zoledronic acid, 1 mg | 143 | $3,436 | None |
| Injection of drug or substance into vein | 73 | $3,186 | $39 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 27 | $3,035 | $21 |
| Injection of additional new drug or substance into vein | 62 | $3,001 | $16 |
| Instillation of anti-cancer drug into bladder | 16 | $2,668 | $89 |
| Administration of chemotherapy into vein, each additional hour | 35 | $2,557 | $29 |
| Administration of additional new drug or substance into vein using push technique | 17 | $2,280 | $58 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 29 | $1,731 | $30 |
| Short return visit | 26 | $1,564 | $54 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 37 | $1,076 | $23 |
| Injection of drug or substance under skin or into muscle | 34 | $860 | $14 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 16 | $824 | $37 |
| New patient visit (15+ min) | 11 | $780 | $71 |
| Injection, fosaprepitant, 1 mg | 24 | $673 | None |
| Infusion into a vein for hydration, each additional hour | 20 | $627 | $13 |
| Injection, ondansetron hydrochloride, per 1 mg | 40 | $83 | None |
| Infusion, normal saline solution, 250 cc | 116 | $82 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 41 | $81 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 28 | $38 | None |
| Unclassified drugs | 11 | $10 | None |
Who their Medicare patients are
601 Original Medicare patients in 2024. Average age 77 · Under 65 3% · 85 and older 18% · Women 63% · Also on Medicaid 4% · Health risk score 1.32. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 60% · Cancer 32% · Coronary heart disease 24% · Chronic kidney disease 22% · Diabetes 16% · Atrial fibrillation 16% · Depression 13% · Heart failure 12% · COPD 9% · Dementia 6% · Stroke 5%.
The office billed $8,716,316, Medicare allowed $3,448,880 and paid $2,750,052; for 125,754 services of 136 kinds; $2,534,997 of it was for drugs given in the office and $215,055 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 601 | 125,754 | 77 | 1.32 | $8,716,316 | $2,750,052 |
| 2023 | 107 | 6,274 | 76 | 1.55 | $500,255 | $170,594 |
| 2019 | 18 | 20 | 63 | 6.10 | $12,650 | $3,471 |
| 2018 | 17 | 17 | 66 | 3.68 | $10,474 | $2,885 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Long return visit (40+ min) | 43 | $9,662 | $170 |
| New patient visit (60+ min) | 24 | $4,785 | $199 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 33 | $4,214 | $29 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 11 | $756 | $69 |
2019: 1 service
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $3,256 | $181 |
2018: 1 service
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,547 | $182 |
Drugs they prescribed that Part D paid
$1,996,547
Pharmacies billed $1,996,547 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 4% of their Part D prescriptions (31 of 722) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.
503 generic and 219 brand-name prescriptions · $1,996,547 in drug cost · 36 antibiotic prescriptions to 16 people · 34 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Revlimid | 15 | $280,680 | $18,712 |
| Pomalyst | 11 | $273,120 | $24,829 |
| Venclexta | 16 | $244,864 | $15,304 |
| Alecensa | 11 | $186,010 | $16,910 |
| Nubeqa | 11 | $149,767 | $13,615 |
See all 18 drugs
| Revlimid | 15 | $280,680 | $18,712 |
| Pomalyst | 11 | $273,120 | $24,829 |
| Venclexta | 16 | $244,864 | $15,304 |
| Alecensa | 11 | $186,010 | $16,910 |
| Nubeqa | 11 | $149,767 | $13,615 |
| Eliquis | 60 | $53,166 | $886 |
| Abiraterone Acetate | 16 | $12,441 | $778 |
| Olanzapine | 34 | $874 | $26 |
| Acyclovir | 51 | $481 | $9 |
| Dexamethasone | 24 | $422 | $18 |
| Anastrozole | 21 | $365 | $17 |
| Ondansetron Odt | 17 | $351 | $21 |
| Prochlorperazine Maleate | 34 | $315 | $9 |
| Sulfamethoxazole-Trimethoprim | 22 | $166 | $8 |
| Gabapentin | 11 | $90 | $8 |
| Lorazepam | 20 | $85 | $4 |
| Prednisone | 18 | $77 | $4 |
| Ondansetron | 15 | $70 | $5 |
Year by year
| 2024 | 722 | 118 | 4% (31) | 30% | $1,996,547 |
| 2023 | 220 | 48 | None | 17% | $199,237 |
| 2022 | 154 | 39 | None | 8% | $219,163 |
| 2021 | 187 | 31 | 7% (13) | 11% | $275,611 |
| 2020 | 110 | 20 | None | 15% | $85,763 |
| 2019 | 27 | 13 | None | None | $2,578 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Eliquis | 11 | $9,960 | $905 |
| Acyclovir | 30 | $674 | $22 |
| Sulfamethoxazole-Trimethoprim | 29 | $430 | $15 |
2022: 3 drugs
| Acyclovir | 11 | $392 | $36 |
| Dexamethasone | 12 | $279 | $23 |
| Sulfamethoxazole-Trimethoprim | 13 | $121 | $9 |
2021: 4 drugs
| Anastrozole | 19 | $407 | $21 |
| Dexamethasone | 20 | $324 | $16 |
| Ondansetron | 14 | $185 | $13 |
| Prochlorperazine Maleate | 13 | $149 | $11 |
2020: 1 drug
| Anastrozole | 12 | $196 | $16 |
Money from drug and device companies
$301 in 2025
| 2025 | 4 | 8 | None | $301 |
| 2024 | 1 | 1 | None | $162 |
| 2023 | 1 | 1 | None | $105 |
| 2022 | 1 | 1 | None | $25 |
| 2021 | 2 | 5 | None | $500 |
| 2020 | 2 | 2 | None | $116 |
| 2019 | 2 | 2 | None | $170 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Daiichi Sankyo | Datroway | $162 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Calquence | $76 | 3 payments
|
| Janssen Biotech | Tremfya | $35 | 1 payment
|
| Caris MPI | Mi Cancer Seek | $27 | 1 payment
|
See all 8 published payments
| Daiichi Sankyo | Meals · 2025-11-21 | Datroway | $22 |
| Daiichi Sankyo | Meals · 2025-10-08 | Datroway | $135 |
| Caris MPI | Meals · 2025-08-25 | Mi Cancer Seek | $27 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-17 | Calquence | $20 |
| Janssen Biotech | Meals · 2025-06-29 | Tremfya | $35 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-14 | Enhertu | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-24 | Calquence | $30 |
| Daiichi Sankyo | Meals · 2025-01-28 | Enhertu | $5 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $162
| AstraZeneca Pharmaceuticals LP | Enhertu | $162 | 1 payment
|
2023: $105
| Genzyme | Enjaymo | $105 | 1 payment
|
2022: $25
| AstraZeneca Pharmaceuticals LP | Lynparza | $25 | 1 payment
|
2021: $500
| Takeda Pharmaceuticals U.S.A. | Iclusig | $325 | 3 payments
|
| Janssen Biotech | Imbruvica | $175 | 2 payments
|
2020: $116
| Seagen | None | $95 | 1 payment
|
| Amgen | None | $21 | 1 payment
|
2019: $170
| Takeda Pharmaceuticals U.S.A. | Velcade | $111 | 1 payment
|
| Stemline Therapeutics | Elzonris | $60 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 84.9 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1891182465
- Licence
- CA 20A15311
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2015-04-22
- NPI last updated
- 2023-09-29
- NPI record certified
- 2023-09-29
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Dr, Stanford, CA, 94305